RALLYBIO CORPORATION Net Income (Loss) Available to Common Stockholders, Basic
RALLYBIO CORPORATION (RLYB) reported Net Income (Loss) Available to Common Stockholders, Basic of -$11.13 million for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-09-09.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2021-09-09
- RALLYBIO CORPORATION net income (loss) available to common stockholders, basic for the quarter ending 2021-06-30 was -$11.13M.
- RALLYBIO CORPORATION net income (loss) available to common stockholders, basic for the quarter ending 2020-06-30 was -$4.89M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month |
|---|---|---|
| 2021-06-30 | -$11.13M 10-Q · filed 2021-09-09 | -$24.40M 10-Q · filed 2021-09-09 |
| 2020-06-30 | -$4.89M 10-Q · filed 2021-09-09 | -$8.77M 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |